CancerSpot, Reliance Industries and Strand Life Sciences

Reliance Industries-powered Strand Life Sciences unveils CancerSpot test for early detection of multiple cancers
Strand Life Sciences, a subsidiary of Reliance Industries, has introduced CancerSpot, a blood-based test for early cancer detection. It employs methylation profiling technology to identify tumor DNA fragments from blood samples.
CancerSpot: A Breakthrough in Early Cancer Detection by Strand Life Sciences
Strand Life Sciences, a subsidiary of Reliance Industries, introduces CancerSpot, a new blood test for early cancer detection using advanced methylation profiling technology. Derived from Indian cohorts,
Reliance subsidiary launches pioneering blood-based test for early detection of multiple cancers
Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumour DNA fragments
Strand Life Sciences Launches Blood Test for Early Cancer Detection
Strand Life Sciences introduces CancerSpot, a blood-based test using methylation profiling for early detection of multiple cancers. The test offers a simple, non-invasive way to identify cancer tumor DNA fragments in blood.
Strand Life Sciences, a Reliance subsidiary, Launches Pioneering Blood-based Test for Early Detection of Multiple Cancers
Leading genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot,
Reliance subsidiary Strand Life Sciences’ blood-based test to detect multiple cancers early-on
Strand Life Sciences launches CancerSpot, a blood-based test for early cancer detection, using advanced methylation profiling technology.
Strand Life Sciences Launches Groundbreaking Cancer Detection Test
Strand Life Sciences introduces CancerSpot, a blood-based test using methylation profiling technology for early detection of multiple cancers. The test aims to address the growing cancer burden in India by offering transformative healthcare solutions.
Strand Life Sciences subsidiary of Reliance Life Sciences launches blood test for early detection of multiple cancers
Strand Life Sciences subsidiary of Reliance Life Sciences launches blood test for early detection of multiple cancers: Our Bureau, Bengaluru Monday, December 2, 2024, 14:40 Hrs [I
Reliance subsidiary Strand Life Sciences launches blood-based test for early detection of multiple cancers
Speaking at the opening of Strand’s new Genomics Diagnostics & Research Centre in Bengaluru, company CEO and Co-Founder Dr. Ramesh Hariharan said that early warning is the key to battle cancer ─ and win it.
Health and Me on MSN1d
Researchers Launch CancerSpot-A Blood test That Could Detect Cancer Even Before Symptoms Appear
Strand Life Sciences has introduced CancerSpot, a blood-based test designed for the early detection of multiple cancers. This ...
Top 5 genetic factors that affect breast cancer risk
Genetic factors significantly influence breast cancer risk, with up to 10% of cases being hereditary. Key risk factors ...